5 Best Stocks to Buy Now According to Michael Platt’s BlueCrest Capital

In this article, we will discuss the 5 best stocks to buy now according to Michael Platt’s BlueCrest Capital. If you want to read our detailed analysis of Platt’s history, his investment strategy, and his hedge-fund performance, go directly to 10 Best Stocks to Buy Now According to Michael Platt’s BlueCrest Capital. 

5. Danaher Corp. (NYSE:DHR)

BlueCrest Capital Management’s Stake Value: $31.9M

Percentage of BlueCrest Capital’s 13F Portfolio: 1.03%

Number of Hedge Fund Holdings: 83

Danaher Corporation (NYSE:DHR) is a globally diversified American conglomerate company based out of Washington D.C. It designs, manufactures and markets medical, industrial, professional and commercial products and services. As of the first quarter of 2022,  Fisher Asset Management is the largest shareholder in the stock, with a total stake value of almost $1.1 billion.

Danaher Corporation (NYSE:DHR) contributes 1.03% to Platt’s 13F investment portfolio. The hedge-fund billionaire owns 108,644 shares worth about $31.9 million, raising his stake in Danaher (NYSE:DHR) by 29%.

On June 1, RBC Capital analyst Deane Dray elevated Danaher Corporation’s (NYSE:DHR) rating to ‘Outperform’, raising the price target to $310 from $299. He observed that the “high quality, defensive portfolio looks incrementally more attractive given the higher Wall of Worry/macro fear”

Cooper Investors Global Equities Fund mentioned Danaher Corporation (NASDAQ:DHR) in their Q1 2022 investor letter. This is what they had to say:

“This combination of attributes was not in favor during a quarter where the market rotated into larger, more traditional index heavyweights that, while growing more slowly and generating lower returns on capital, typically trade on lower headline multiples. In Healthcare for example, we saw portfolio holdings Danaher (NASDAQ:DHR) fall 10-15% in the quarter. Given the relative business quality and growth prospects for a life sciences capital allocator champion like Danaher (NASDAQ:DHR) versus a large diversified pharma company, we think this period of underperformance is likely more a blip than a trend.”